Prevention of @entity35 mammary carcinoma utilizing XXXX as an equivalent to oophorectomy.

@entity172 @entity3086 @entity2847 @entity0 @entity5 @entity53 @entity106 @entity35 @entity105
A clinical trial is currently under way to examine the effectiveness of @entity3086 as a @entity0 chemopreventive agent and contraceptive. This trial, as well as similar proposed studies, is based on the assumption that @entity3086 is as effective as surgical castration in preventing the onset of @entity5 ; however, this has not been well documented in the @entity106 animal model. We directly compared @entity3086 and oophorectomy in this model and examined a combined therapy of @entity3086 / @entity2847 . Twenty-seven day old female @entity35 were randomly allocated into one of eight groups. All @entity35 received a 20-mg dose of @entity106 at the age of 55 days. Group 1 (n = 10), no treatment; Group 2 (n = 9), @entity3086 (100 microg/kg/day) for eight weeks beginning four weeks prior to @entity106 ; Group 3 (n = 10), oophorectomy four weeks prior to @entity106 with replacement @entity172 beginning four weeks following @entity106 . @entity172 replacement was achieved with a 0.05-mg @entity53 tablet releasing 0.833 microg/day over a 60-day period. Group 4 (n = 10), @entity3086 (100 microg/kg/day) initiated two weeks prior to @entity106 and continuing for two weeks following @entity106 ; Group 5 (n = 9), oophorectomy two weeks prior to @entity106 with 0.05 mg of @entity53 in depot form, releasing 0.833 microg/day, beginning four weeks following @entity106 and continuing until week 16 of the study; Group 6 (n = 10), @entity3086 (100 microg/kg/day) beginning two weeks prior to @entity106 and continuing for the duration of the experiment; Group 7 (n = 10), @entity3086 (100 microg/kg/day) for eight weeks beginning two weeks prior to @entity106 ; Group 8 (n = 9), @entity3086 (100 microg/kg/day) and @entity2847 (83 microg/day) for eight weeks beginning two weeks prior to @entity106 . At nineteen weeks (15 weeks post @entity106 ), animals were sacrificed and autopsies performed. One hundred percent of untreated animals developed @entity5 . No animals undergoing oophorectomy four weeks prior to @entity106 or receiving @entity3086 four weeks prior to and simultaneously with @entity106 developed @entity5 . In animals pretreated two weeks prior to @entity106 with @entity3086 or oophorectomy, each group had one animal with @entity5 development. No @entity5 developed in the animals receiving ongoing injections of @entity3086 . However, one @entity5 developed in those receiving @entity3086 for the first eight weeks beginning two weeks prior to @entity106 administration. One animal receiving both @entity3086 and @entity2847 developed one @entity5 . We conclude that chemical oophorectomy (with @entity3086 ) is as effective as surgical oophorectomy in inhibiting @entity106 induced @entity105 .
